RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
 Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Health Channel

subscribe to Health newsletter
Health

   EMAIL   |   PRINT
The controversial history of Post-Menopausal Hormone Therapy

Feb 21, 2005 - 12:03:00 AM
“From a purely business point of view, the most reliable profits [for drug companies] can be made from disease processes and conditions that have high incidence and prevalence,”

 
[RxPG] There is a widespread controversy regarding the risks and benefits of hormone therapy (HT) for post-menopausal women with no end in sight. Roughly 45 million women in the US are post-menopausal and HT has been the predominant form of treatment for most of the twentieth century. But the history of these drugs (estrogen and estrogen plus progestin) illustrates a complex drama where different stakeholders with competing objectives can and did produce health practices and policies of questionable benefit. A critical analysis publishing in the recent issue of the Journal of Social Issues examines the back-story and key stakeholders—including the women who the authors say, “emerge as both willing participants and unwilling victims of the unintended consequences of these drugs.”

Post-menopausal HT began as, and is still prescribed as, a treatment to the severe to moderate symptoms that arise around menopause. It became a potential long-term therapy for the prevention and treatment of the most common causes of morbidity and mortality of women, e.g. heart disease, osteoporosis, and dementia—uses that were not approved by the FDA. But controlled studies found that there was no benefit for women’s health-related quality of life, but there was increased risk in breast cancer, increase in cardiovascular events and stroke risk among other results leaving the stakeholders in a dilemma. “From a purely business point of view, the most reliable profits [for drug companies] can be made from disease processes and conditions that have high incidence and prevalence,” the authors state. Post-menopausal symptoms provide drug companies such an opportunity, even for those with drugs that create positive results, i.e. prevent heart disease. For physicians their professional credibility is affected and for women it’s personal. HT once held the promise of regained femininity and the prolongation of youth- now it holds controversy.



Publication: This study is published in the current issue of Journal of Social Issues
On the web: The Society for the Psychological Study of Social Issues. 

Advertise in this space for $10 per month. Contact us today.


Related Health News


Subscribe to Health Newsletter

Enter your email address:


 Additional information about the news article
This study is published in the current issue of Journal of Social Issues. For a PDF of this article please contact [email protected]

Journal of Social Issues brings behavioral and social science theory, empirical evidence, and practice to bear on human and social problems. Each issue of the journal focuses on a single topic - recent issues, for example, have addressed poverty, housing and health; privacy as a social and psychological concern; youth and violence; and the impact of social class on education. It is published on behalf of The Society for the Psychological Study of Social Issues.

Michelle Naughton is an Associate Professor in the Department of Public Health Sciences at the Wake Forest University School of Medicine. She is also a Co-Investigator of the Clinical Facilitation Center for the Women’s Health Initiative.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)